Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Sung-Hyun Kim,¹ Hari Menon,² Saengsuree Jootar,³ Tapan Saikia,⁴ Jae-Yong Kwak,⁵ Sang-Kyun Sohn,⁶ Joon Seong Park,⁷ Seong Hyun Jeong,⁷ Hyeoung Joon Kim,⁸ Yeo-Kyeoung Kim,⁸ Suk Joong Oh,⁹ Hawk Kim,¹⁰ Dae Young Zang,¹¹ Joo Seop Chung,¹² Ho Jin Shin,¹² Young Rok Do,¹³ Jeong-A Kim,¹⁴ Dae-Young Kim,¹⁵ Chul Won Choi,¹⁶ Sahee Park,¹⁷ Hye Lin Park,¹⁸ Gong Yeal Lee,¹⁸ Dae Jin Cho,¹⁸ Jae Soo Shin,¹⁸ and Dong-Wook Kim^{17,19}

¹Dong-A University Medical Center, Busan, South Korea; ²Tata Memorial Hospital, Parel, Mumbai, India; ³Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; ⁴Prince Aly Khan Hospital, Mazagaon, Mumbai, India; ⁵Chonbuk National University Medical School & Hospital, Jeonju, South Korea; ⁶Kyungpook National University Hospital, Daegu, South Korea; ⁷Ajou University Hospital, Suwon, South Korea; ⁸Chonnam National University, Hwasun Hospital, Hwasun, South Korea; ⁹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; ¹⁰Ulsan University Hospital, Ulsan, South Korea; ¹¹Hallym University Sacred Heart Hospital, Anyang, South Korea; ¹²Pusan National University Hospital, Pusan, South Korea; ¹³Dongsan Medical Center, Keimyung University, Daegu, South Korea; ¹⁴St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea; ¹⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; ¹⁶Korea University, Guro Hospital, Seoul, South Korea; ¹⁷Cancer Research Institute, It-YANG Pharm. Co. Ltd., Yongin, South Korea; and ¹⁹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.096776 Manuscript received on August 15, 2013. Manuscript accepted on March 31, 2014. Correspondence: dwkim@catholic.ac.kr

Online Supplementary Figure S1

